Robert E. Gagnon
Independent DirectorMr. Robert E. Gagnon, also known as Rob, CPA, MBA serves as an Independent Director of Bone Biologics Corporation since January 08, 2024. He serves as Chief Financial Officer since September 2025 at Opus Genetics, Inc. and is its Principal Accounting Officer from September 2, 2025. He serves as Director at Harvard Bioscience, Inc. since July 16, 2025. He serves as on the Board of Directors at Purple Biotech Ltd. He served as Director of Verastem, Inc. since December 13, 2022 until May 21, 2026. He was Chief Financial Officer at Remix Therapeutics Inc. since March 2023. He was the Chief Financial Officer and Operating Partner at Gurnet Point Capital Limited. He was former Chief Business Officer and Chief Financial Officer at Verastem Oncology. His expertise in all areas of biopharmaceutical finance, including his ability to navigate complex business challenges, combined with his deep understanding of Verastems goals and operations. He has financial and commercial experience in Heading global finance operations. He serves as Independent Director at Purple Biotech Ltd. since March 2021. Mr. Gagnon had been the Chief Financial Officer of Verastem, Inc. since August 28, 2018 until October 31, 2022 and served as Chief Business Officer since June 2019 until October 31, 2022. He served as Chief Financial Officer of Harvard Bioscience Inc. Since November 2013 until August 28, 2018 and also served as its Treasurer till August 28, 2018. He served as the Chief Financial Officer of Xenetic Biosciences, Inc. since July 2013. He served as Chief Finance Officer of General Sales & Leasing, Inc. since January 2014. He served as an Executive Vice President of Finance at Harvard Bioscience Inc. since October 23, 2013. He served as the Chief Financial Officer, Executive Vice President and Treasurer of Clean Harbors, Inc. since August 20, 2012 until February 04, 2013. From joining in 2005 to July 2012, Mr. Gagnon served in various positions at Biogen Idec, a public pharmaceuticals company. He served as Vice President of Business Planning of Biogen Idec Inc. since February 1, 2012 and served as its Controller since November 3, 2010. He served as the Chief Accounting Officer of Biogen Idec Inc. from November 3, 2010 to April 2, 2012. He served as Vice President of Biogen Idec from November 3, 2010 to February 1, 2012. Mr. Gagnon served as Vice President of Finance at Biogen Idec from July 2007 to November 2010 and its Director of Corporate Accounting from October 2005 to July 2007. He worked for PWC from 1995 to 1999 and served as its Senior Manager in the Audit and Assurance Services division. He served as Senior Director of Biogen Idec. He was a Senior Audit Manager and certified public accountant at Deloitte & Touche, LLP and PricewaterhouseCoopers, LLP. He was Corporate Controller at eRoom Technology. A Certified Public Accountant, Mr. Gagnon holds an MBA degree with a finance concentration from MIT Sloan School of Management and a BA degree in Accounting from Bentley College in 1995.
Positions
- Company NameBone Biologics CorporationStock CodeBBLGPositionIndependent Director
- Company NameHarvard Bioscience, Inc.Stock CodeHBIOPositionIndependent DirectorColleagues
- JDJohn DukePresident, CEO, Director & Member of Scientific Advisory Board
- MTMark T. FrostCFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
- LPLori PackerVice President of Global People Operations
- DPDavid PanzarellaSenior Vice President of Commercial
- KFKathryn FlynnCorporate Controller
- RERobert E. GagnonIndependent Director
- KAKatherine A. EadeLead Independent Director
- SJStephen J. DeNelskyIndependent Director
- SBSeth BensonIndependent Director
- Company NameOpus Genetics, Inc.Stock CodeIRDPositionCFO & Principal Accounting Officer
